{"filings":[{"id":1481357,"accession_number":"0001193125-26-296936","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-07-07T12:15:15+00:00","items":["7.01","9.01"],"status":"ready","headline":"Breakthrough T1D awards grant for SAB-142 study in Stage 3 T1D beyond 100 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Breakthrough T1D awarded grant to Dr. Michael Haller (U. Florida) for PRISE-hATG study of SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.","Study aims to assess SAB-142's ability to preserve C-peptide and modulate immune responses in patients with residual beta cell function beyond 100 days.","SAB BIO will co-fund the study; it complements ongoing Phase 2b SAFEGUARD trial in new onset Stage 3 T1D.","CEO Samuel Reich says SAB-142 has potential as best-in-class disease-modifying therapy for T1D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139476,"accession_number":"0001193125-26-275976","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-06-18T20:35:15+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics stockholders elect four Class II directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Zaccardelli, Katie Ellias, David Link, and Andrew Moin elected as Class II directors with 48.3M, 48.3M, 44.1M, and 44.2M votes for, respectively.","EisnerAmper LLP ratified as independent auditor for FY2026: 59.3M votes for, 3,373 against, 26,798 abstentions.","Quorum of 59.3M shares (76.12% of outstanding) present at June 18, 2026 meeting.","Broker non-votes of 10,994,436 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96000,"accession_number":"0001193125-26-204125","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics signs manufacturing deal with Emergent for SAB-142; $36M minimum spend post-FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.","Term runs 5 years from FDA approval; minimum aggregate spend of $36 million after approval.","Emergent has exclusive manufacturing rights during term; SAB may seek alternative source in limited cases.","Commercial batch price to be set in amendment within 18 months of anticipated commercial sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95999,"accession_number":"0001193125-26-168569","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB BIO reports positive Phase 1 SAB-142 data: C-peptide preservation, T cell exhaustion, improved glycemic control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.","SAB-142 induced CD4+ Tconv cell exhaustion (TIGIT+ levels) correlating with C-peptide preservation, consistent with rabbit ATG mechanism.","Mean CGM time in range improved from 73% at baseline to 85% at Day 120, with no increase in exogenous insulin use.","Phase 2b SAFEGUARD trial topline data expected in 2H 2027; CEO cites potential best-in-class profile for T1D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109493,"accession_number":"0001193125-26-114730","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.","Gross proceeds expected ~$85M; net proceeds ~$69.7M ($81.7M if over-allotment option exercised).","Proceeds to fund clinical development of SAB-142 (anti-thymocyte immunoglobulin) for type 1 diabetes.","Offering led by Jefferies, UBS, Citigroup, Barclays; expected to close March 19, 2026.","30-day over-allotment option for additional 3.31M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109492,"accession_number":"0001193125-26-099376","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.","Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.","Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.","SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.","Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109491,"accession_number":"0001193125-26-010515","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics posts updated corporate presentation; no financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 Regulation FD; presentation posted on company website.","No specific financial metrics, pipeline updates, or guidance changes provided in the filing.","Presentation titled 'Modifying Disease, Delaying Progression, Transforming Treatment' suggests therapeutic focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109490,"accession_number":"0001193125-26-005487","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.","Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.","Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.","Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126007,"accession_number":"0001193125-25-335267","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.","Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.","Net proceeds intended for pipeline development, general corporate and working capital purposes.","Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142741,"accession_number":"0001193125-25-225119","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Christine Hamilton and Jeffrey Spragens resign from SAB Biotherapeutics board; size cut to nine","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine Hamilton and Jeffrey Spragens resigned as board members effective September 30, 2025.","Board size reduced from 11 to 9 directors, per July 2025 letter agreement with RA Capital Healthcare Fund.","Resignations were not the result of any disagreement with management or company policies.","The changes follow terms of the company's July 2025 private placement of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142740,"accession_number":"0001193125-25-220721","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"SAB Biotherapeutics shareholders approve 24.18M share increase and Series B conversion at less than minimum price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.","Approved issuance of over 19.99% of outstanding common stock upon Series B Preferred conversion at less than Nasdaq minimum price, deemed a potential change of control.","Proposal 1 (conversion) passed with 5,502,026 votes for, 515,275 against, 35,744 abstentions.","Proposal 2 (plan amendment) passed with 5,089,862 votes for, 951,598 against, 11,585 abstentions.","Approximately 54.5% of outstanding shares were present, forming a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142739,"accession_number":"0000950170-25-097078","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","3.02","8.01","5.03","9.01"],"status":"ready","headline":"SAB Bio raises $175M in oversubscribed private placement; Sanofi participates; cash runway into mid-2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.","Investors include strategic partner Sanofi, RA Capital, Commodore Capital, Vivo Capital, Blackstone Multi-Asset, and others.","Proceeds to fully fund Phase 2b SAFEGUARD study of SAB-142 in Stage 3 T1D and extend cash runway into middle of 2028.","Warrants exercisable for up to 1.5M additional preferred shares, potentially yielding additional $284M in gross proceeds.","Company received FDA alignment on Phase 2b SAFEGUARD trial design during a Type B meeting on May 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142738,"accession_number":"0000950170-25-096645","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics elects four Class I directors, ratifies auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Dr. William Polvino, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler as Class I directors for three-year terms.","Appointment of EisnerAmper LLP as independent auditor for fiscal year 2025 ratified with 6,374,363 votes for, 238,327 against.","Quorum of 71.38% achieved; 6,633,125 shares present out of 9,291,697 outstanding.","Broker non-votes of 2,154,677 on director elections; each director received over 4.3 million votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179017,"accession_number":"0000950170-25-014627","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"SAB Biotherapeutics enters 5-year lease for Sioux Falls lab/office space from Sanford Health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases 21,014 sq ft at 2301 E 60th St N, Sioux Falls, SD; term effective Feb 1, 2025 through Dec 31, 2029.","Annual rent $601,630.82 ($28.63/sq ft), paid monthly at $50,135.90; January 2025 rent paid under prior lease.","Annual rent escalates by greater of 2% or CPI starting Jan 1, 2026; either party may terminate with 90 days' notice.","Tenant responsible for maintenance and repairs; Landlord pays utilities, taxes, and base-building maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179016,"accession_number":"0000950170-25-009474","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics reports positive Phase 1 topline results for T1D therapy SAB-142; plans Phase 2b in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.","SAB-142 showed sustained immunomodulation with MoA analogous to rabbit ATG, correlative to C-peptide preservation.","Company plans to advance SAB-142 into Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.","Results presented at R&D webinar on Jan 28, 2025; KOL Michael Haller, MD from Univ of Florida participated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211971,"accession_number":"0000950170-24-104564","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.","Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.","Topline Phase 1 data readout expected by end of 2024.","SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211970,"accession_number":"0000950170-24-088247","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.","To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.","Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.","Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230788,"accession_number":"0000950170-24-078622","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.","Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.","Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.","Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230787,"accession_number":"0000950170-24-066856","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics CFO Michael King resigns effective June 4; Mark Conley appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael King resigns effective June 4, 2024 to become CEO at private oncology company; will remain advisor through year-end.","Mark Conley, current VP Finance, appointed Interim CFO; board launches formal search for permanent replacement.","Conley's compensation unchanged under existing agreement: $303K base salary, bonus eligibility, and 250,000 stock options.","Company confirms FY2024 outlook and upcoming Phase 1 topline data readout for lead candidate SAB-142."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230786,"accession_number":"0000950170-24-062656","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.","Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).","Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.","Topline results from the MELD-ATG study expected in 2025.","SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230785,"accession_number":"0000950170-24-054868","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics Appoints Dr. Jay Skyler to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Skyler appointed as Class I director, effective May 3, 2024, to serve until 2025 annual meeting.","Skyler is Professor of Medicine at University of Miami, former President of American Diabetes Association, and served on boards of DexCom, Amylin, and MiniMed.","His appointment brings deep Type 1 diabetes expertise to SAB's board, supporting SAB-142 immunotherapy program.","No material transaction or family relationship with any director or officer; compensation consistent with non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230784,"accession_number":"0000950170-24-044497","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"SAB Biotherapeutics completes dosing of cohort 3 for SAB-142 Phase 1 trial; no serum sickness observed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Completed dosing of cohort 3 in Phase 1 trial of SAB-142.","No instances of serum sickness reported.","Company to issue corporate update press release on or about April 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249171,"accession_number":"0000950170-24-038429","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.","Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.","Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.","Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.","R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249170,"accession_number":"0000950170-24-028666","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"SAB Biotherapeutics enters new exec employment agreements with President and COO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President Eddie J. Sullivan gets annual base salary of $485,000; eligible for bonus up to 50% of salary.","COO Christoph Bausch gets annual base salary of $425,000; eligible for bonus up to 40% of salary.","Agreements effective Jan 1, 2024, replacing prior employment pacts; standard non-compete and non-solicit included.","No changes to board or officer composition; both executives remain in same roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249169,"accession_number":"0000950170-24-010093","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Samuel J. Reich appointed CEO of SAB Biotherapeutics; remains Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Reich expands role from Executive Chairman to CEO effective February 2, 2024.","Co-founder Eddie J. Sullivan continues as President and board member, leading operations and R&D.","Reich co-founded Biscayne Neurotherapeutics (sold to Supernus) and Acuity Pharmaceuticals.","Company advancing lead candidate SAB-142 for delaying type 1 diabetes progression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249168,"accession_number":"0000950170-24-007941","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics signs $20M ATM equity offering with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows sale of up to $20M of common stock through Cantor as sales agent.","Agent will receive 3.0% of gross proceeds per sale; no minimum obligation to sell.","Net proceeds to fund pipeline development and general corporate/working capital.","Agreement is terminable by either party on ten days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249167,"accession_number":"0000950170-24-007480","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.","Company conducted a 1-for-10 reverse stock split on Jan 5, 2024 to help meet the $1.00 minimum close.","Common shares met $1.00 closing bid for 10 consecutive trading days, ending the deficiency.","Prior non-compliance notice was issued Jan 23, 2023; Nasdaq has now closed the matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249166,"accession_number":"0000950170-24-005793","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics posts updated corporate presentation; no material news in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing announces availability of an updated corporate presentation on company website.","No financial results, guidance changes, or specific operational updates disclosed in the 8-K.","Presentation is furnished under Regulation FD and not incorporated by reference.","Tickers SABS and SABSW trade on Nasdaq; no news affecting them directly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249165,"accession_number":"0000950170-24-000543","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics effects 1-for-10 reverse stock split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 12:01 a.m. ET Jan 5, 2024; reduces outstanding shares from ~92.25M to ~9.225M.","Stockholders approved at Jan 2, 2024 special meeting with 59,076,836 votes for, 3,409,403 against.","Warrants (SABSW) adjusted: every 10 warrants now exercisable for 1 share at $115.00 per share.","New CUSIP for common stock (SABS) is 78397T202; fractional shares paid in cash.","Split intended to bring SABS above Nasdaq minimum bid price requirement and maintain listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266672,"accession_number":"0000950170-23-066553","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics dosed first participants in Phase 1 trial of SAB-142 for Type 1 Diabetes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human Phase 1 trial dosed in Australia; double-blind, placebo-controlled, single-ascending dose design.","SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin targeting immune cells that destroy pancreatic beta cells.","Phase 1 assesses safety, tolerability, PK/PD, and aims to establish proof of biological activity in T1D.","Company plans to file IND with FDA and CTA in UK/EU in 2024 to advance to Phase 2b study.","Trial led by Dr. Kristi McLendon at Nucleus Network; SAB-142 has potential as disease-modifying treatment for T1D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266671,"accession_number":"0000950170-23-065895","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"SAB Biotherapeutics shareholders approve increase in authorized common stock and preferred stock conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 490M to 800M shares on Nov 22, 2023.","Proposal 1 received 40,768,042 votes for, 1,732,365 against, and 375,532 abstentions.","Shareholders also approved potential issuance >19.99% of outstanding common stock upon conversion of Series A Preferred Stock.","Proposal 2 received 33,420,475 votes for, 352,390 against, 376,812 abstentions, and 8,726,262 broker non-votes.","The conversion involves Series A-1, A-2, and A-3 Convertible Preferred Stock under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266670,"accession_number":"0000950170-23-065178","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics appoints Katie Ellias to Board of Directors, effective Nov 20, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Katie Ellias as Class II director, effective Nov 20, 2023, until 2026 annual meeting.","Ellias is Managing Director at JDRF T1D Fund (~$200M assets), which invested in SAB.","Board now has 10 directors, 8 independent.","Ellias brings T1D expertise; formerly at Endeavour Vision, Sofinnova Partners, Medtronic, McKinsey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266667,"accession_number":"0000950170-23-063774","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K/A","filed_at":"2023-11-14T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.","Exercised Tranche A warrants: 59,654 additional shares for $59.654M by Nov 14.","Investors assumed 16,269 unexercised warrants; received new Tranche B and C warrants.","Outstanding now: 42,846 Tranche B warrants ($42.846M) and 107,115 Tranche C warrants ($107.115M).","Unexercised Tranche A warrants and remaining Tranche B/C warrants cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266669,"accession_number":"0000950170-23-056048","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Appoints Michael King as CFO with $450K salary and 850K share option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.","Base salary $450,000, target annual bonus of 40% of base, and 850,000 stock options.","Options vest over 4 years: 25% on 1-year anniversary, then monthly over 36 months.","King has 25+ years in biotech research; most recently Co-Head of Healthcare at EF Hutton.","No family relationships or arrangements with others influenced his selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266668,"accession_number":"0000950170-23-051127","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01","3.02","8.01","5.02","5.03","9.01"],"status":"ready","headline":"SAB Biotherapeutics announces up to $130M private placement led by RA Capital to fund SAB-142 T1D trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of $7.5M from Series A-1 Preferred; potential total $130M via warrants and further tranches.","Funds to advance SAB-142 into Phase II for type 1 diabetes; Phase I expected Q4 2023.","Investors include RA Capital, BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, JDRF T1D Fund.","Andrew Moin (Sessa Capital) appointed to Board of Directors effective upon closing.","Preferred stock convertible at $0.63/share; requires stockholder approval; warrants exercisable for additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283919,"accession_number":"0000950170-23-043561","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics appoints EisnerAmper as new auditor after MHM resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["EisnerAmper LLP engaged as independent auditor for FY 2023 and Q3 2023 review, effective Aug 18, 2023.","Audit Committee and Board unanimously approved the engagement; no prior consultations with EisnerAmper occurred.","MHM resigned as auditor on Aug 21, 2023, as previously reported on July 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283918,"accession_number":"0001437749-23-021186","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor MHM declines re-election as SAB Biotherapeutics' independent auditor; going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MHM notified SAB Biotherapeutics on July 25, 2023 it will not stand for re-election as auditor for FY 2023.","MHM to cease as auditor by earlier of new firm engagement, Q2 2023 10-Q filing, or August 21, 2023.","MHM's audit reports for 2021-2022 included a going concern explanatory paragraph and a material weakness in internal controls leading to a restatement.","Company is in process of selecting a new independent registered public accounting firm; no successor named yet.","MHM furnished a letter to the SEC (Exhibit 16.1) agreeing with the company's statements in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283917,"accession_number":"0001437749-23-019198","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics shareholders elect Spragens and Link as Class II directors, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Jeffrey G. Spragens and David Link as Class II directors for three-year terms expiring at 2026 annual meeting.","Appointment of Mayer Hoffman McCann P.C. as independent auditor for FY 2023 ratified with 37.25M votes for, 33K against.","Over 37.5M shares voted, representing 74.45% of outstanding shares, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303508,"accession_number":"0001437749-23-017924","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).","SAB-142 modulates key T-cell subsets similarly to rabbit ATG in vivo, confirming mechanism.","Plans to submit IND for SAB-142 to FDA and initiate Phase 1 trial in coming months.","Over 8.4M people affected by T1D worldwide; only one disease-modifying treatment available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303507,"accession_number":"0001437749-23-017353","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics holds virtual R&D Day; reviews platform and recent designations","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented portfolio update including recent Breakthrough Therapy and Fast Track designations.","Highlighted programs: influenza, C. diff, type 1 diabetes (SAB-176, SAB-185, SAB-142, SAB-195).","No new financial guidance, clinical data, or material business changes disclosed.","Presentation furnished as Exhibit 99.1 but not text-available; summary based on filing narrative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303506,"accession_number":"0001437749-23-014272","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics announces Fast Track and Breakthrough Therapy designations for SAB-176 anti-influenza candidate","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track Designation granted by FDA for SAB-176, an anti-influenza polyclonal antibody therapy.","Breakthrough Therapy Designation also received for SAB-176, potentially expediting development and review.","Company published an updated corporate strategy presentation on its website discussing these designations and platform.","SAB-176 targets influenza; regulatory milestones may accelerate clinical timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303505,"accession_number":"0001437749-23-011514","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).","Median time to symptom resolution was 7 days shorter for SAB-185 vs REGEN-COV (p=0.010).","Primary endpoint (hospitalization/death) inconclusive due to low events after Omicron emergence.","Grade 3+ adverse event rates similar between SAB-185 and REGEN-COV arms.","SAB-176 for influenza granted Fast Track and Breakthrough Therapy designations from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303504,"accession_number":"0001437749-23-010655","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics receives FDA Breakthrough Therapy Designation for influenza therapeutic SAB-176","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to SAB-176 for post-exposure prophylaxis of Type A/B influenza in high-risk patients.","SAB-176 previously received Fast Track designation on April 13, 2023; both designations rarely obtained together.","Breakthrough Therapy provides intensive FDA guidance, eligibility for priority review, and expedited development.","SAB-176 is a fully human multi-epitope binding polyclonal antibody, reducing risk of viral escape mutations.","Phase 2b dose-ranging efficacy and safety trial planned following FDA regulatory alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303503,"accession_number":"0001437749-23-010220","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics receives FDA Fast Track Designation for SAB-176 influenza immunotherapy for high-risk patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track Designation granted for SAB-176, an investigational therapeutic for Type A and B influenza in high-risk patients, including those with antiviral-resistant strains.","FDA aligned on Phase 2b trial design evaluating safety and efficacy in high-risk patients; manufacturing approach also aligned.","SAB-176 is a fully-human polyclonal IgG antibody produced without human donors via the DiversitAb platform.","Phase 2a data showed broad cross-protection against multiple influenza strains, including non-targeted strains.","The designation enables frequent FDA interactions, priority review, and rolling review eligibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303502,"accession_number":"0001437749-23-009184","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics appoints Erick Lucera, former AVEO CFO, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Lucera appointed to SAB Biotherapeutics Board effective April 4, 2023; term until next annual meeting.","Lucera most recently served as CFO of AVEO Oncology through its acquisition by LG Chem; prior CFO at Valeritas and Viventia Bio.","With 30+ years in biotech/med device finance, he brings experience in corporate finance, M&A, and public offerings.","Compensation consistent with other non-employee directors as described in the 2022 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323156,"accession_number":"0001437749-23-008871","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"SAB Biotherapeutics restates 2021 financials, delays 10-K; reports $15M cash, reduced burn","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement of 2021 financials due to misclassification of insurance financing; no net income impact, but prior statements should no longer be relied upon.","Cash and equivalents $15.0M as of Dec 31, 2022 (down from $33.2M); annualized cash consumption reduced to $18M from $60M.","Received $16.8M total from US government settlement for COVID-19 therapeutic SAB-185; first $8.6M in Nov 2022, second $8.2M in Jan 2023.","Raised $7.9M in private placement; appointed new CMO Alexandra Kropotova and board member Scott Giberson.","Pipeline progress: SAB-142 type 1 diabetes IND-enabling studies completed; SAB-176 influenza Phase 2a data; SAB-195 C. diff program initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323155,"accession_number":"0001437749-23-007867","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["2.03","3.02"],"status":"ready","headline":"SAB Biotherapeutics settles Ladenburg lawsuit; issues warrant and agrees to pay $3.1M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Issued warrant for 300,000 shares at $0.5424 per share and paid $500K cash upfront.","Must pay $1.5M by June 30, 2023, and $1.1M by Dec 31, 2023, in cash or stock at Company's option.","Ladenburg Action will be dismissed with prejudice after obligations completed.","Warrant issued under Section 4(a)(2) and Rule 506 of Regulation D as unregistered sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323154,"accession_number":"0001437749-23-002624","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics presents DiversitAb platform and clinical data at BIO CEO Conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation highlighted DiversitAb platform and completed trial data showing polyclonal antibody efficacy against mutating pathogens.","No specific financial results or forward guidance were disclosed in the 8-K or presentation summary.","Audio recording and presentation slides made available on Company's IR website prior to conference.","Information furnished under Item 7.01 and not deemed filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323153,"accession_number":"0001437749-23-001990","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SAB Biotherapeutics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 23, 2023; common stock bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days (until July 24, 2023) to regain compliance by closing bid price >= $1.00 for 10 consecutive days.","If not compliant, may apply for additional 180-day period; reverse stock split is a potential cure.","No immediate effect on listing; company monitoring and evaluating options to regain compliance.","Failure to regain compliance could lead to delisting from the Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323152,"accession_number":"0000950170-23-000576","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics completes GLP-tox study for SAB-142 T1D therapeutic; IND filing within 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SAB-142 well tolerated in GLP-tox study; dose-dependent pharmacologic effect confirmed.","First fully-human anti-thymocyte hpAB for type 1 diabetes; may avoid immune reactions seen with animal-derived antibodies.","SAB to submit IND filing within approximately 12 months.","SAB-142 dosed at 1, 5, and 10 mg/kg; prolonged lymphodepletion suggests potential for optimized dosing.","Potential to delay onset/progression of type 1 diabetes and other T-cell mediated autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-10T23:59:59+00:00|323152"}